J Cancer Res Clin Oncol: Real-world data from the First Hospital of Guangzhou Medical University found that Sintilimab (sintilimab) combined with paclitaxel + platinum may further improve the survival of advanced lung squamous cell carcinoma

The ORIENT-12 study shows that Sintilimab (sintilimab) combined with gemcitabine and platinum (GP) has a good effect in patients with squamous non-small cell lung cancer (sqNSCLC)
.

However, the efficacy of Sintilimab (sintilimab) + paclitaxel/albumin-bound paclitaxel + platinum (TP) in the treatment of sqNSCLC is unclear

The ORIENT-12 study shows that Sintilimab (sintilimab) combined with gemcitabine and platinum (GP) has a good effect in patients with squamous non-small cell lung cancer (sqNSCLC)

The study included 52 patients from January 2019 to January 2021, and they were divided into Sintilimab + TP (Group A, n=32, 61.
5%) and Sintilimab + GP (Group B, n=20) , 38.
5%)
.

The median age of all patients was 61 years (range 46-84 years)

The study included 52 patients from January 2019 to January 2021, and they were divided into Sintilimab + TP (Group A, n=32, 61.

The ORR of group A was 59.

Efficacy evaluation

Efficacy evaluation

The median progression-free survival (PFS) of group A was 10.
9 months (95% CI, 5.
0-16.
7), and group B was 7.
5 months (95% CI, 4.
0-10.
9) (HR, 0.
64; 95% CI, 0.
30 1.
4; P = 0.
24)
.

The 12-month PFS rate in group A was 44.

The median progression-free survival (PFS) of group A was 10.

               Differences in PFS between the two groups and subgroup analysis

Differences in PFS between the two groups and subgroup analysis

The median OS in group A was 20.
1 months (95% CI, 13.
6 26.
6), and in group B 16.
3 months (95% CI, 2.
9 29.
6) (HR, 0.
69; 95% confidence interval, 0.
26 1.
84; P = 0.
46 )
.

The 1-year OS rate in group A was 72.

The median OS in group A was 20.

                Differences in OS between the two groups and subgroup analysis

Differences in OS between the two groups and subgroup analysis

AEs occurred in both groups of patients
.

The incidence of ≥3 grade AEs in the two groups was divided into 37.

AEs occurred in both groups of patients

Immune-mediated adverse events (irAEs) occurred in 12 (40.
6%) of 32 patients in group A, and 9 (45.
0%) of 20 patients in group B occurred immune-mediated adverse events; AEs of grade 3 and above were 3 cases (9.
1%) and 1 case (5.
0%)
.

 

In summary, studies have shown that Sintilizumab+TP and Sintilizumab+GP have similar efficacy in the first-line treatment of patients with advanced or metastatic sqNSCLC
.

In summary, studies have shown that Sintilizumab+TP and Sintilizumab+GP have similar efficacy in the first-line treatment of patients with advanced or metastatic sqNSCLC
.
Studies have shown that Sintilizumab+TP and Sintilizumab+GP have similar efficacy in the first-line treatment of patients with advanced or metastatic sqNSCLC
.
Studies have shown that Sintilizumab+TP and Sintilizumab+GP have similar efficacy in the first-line treatment of patients with advanced or metastatic sqNSCLC
.

 

Original source:

Original source:

Xinqing Lin, Haiyi Deng, Suyang Li, et al.
Sintilimab With Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Squamous Non-small-cell Lung Cancer: Real-world Data Study.
DOI: https://doi.
org/ 10.
21203/rs.
3.
rs-991261/v1.

Xinqing Lin, Haiyi Deng, Suyang Li, et al.
Sintilimab With Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Squamous Non-small-cell Lung Cancer: Real-world Data Study.
DOI: https://doi.
org/ 10.
21203/rs.
3.
rs-991261/v1.
Leave a message here